LLY

1,041.67

-0.67%↓

JNJ

203.38

+0.19%↑

ABBV

229.55

-1.49%↓

UNH

311.75

+0.84%↑

AZN

88.67

-0.36%↓

LLY

1,041.67

-0.67%↓

JNJ

203.38

+0.19%↑

ABBV

229.55

-1.49%↓

UNH

311.75

+0.84%↑

AZN

88.67

-0.36%↓

LLY

1,041.67

-0.67%↓

JNJ

203.38

+0.19%↑

ABBV

229.55

-1.49%↓

UNH

311.75

+0.84%↑

AZN

88.67

-0.36%↓

LLY

1,041.67

-0.67%↓

JNJ

203.38

+0.19%↑

ABBV

229.55

-1.49%↓

UNH

311.75

+0.84%↑

AZN

88.67

-0.36%↓

LLY

1,041.67

-0.67%↓

JNJ

203.38

+0.19%↑

ABBV

229.55

-1.49%↓

UNH

311.75

+0.84%↑

AZN

88.67

-0.36%↓

Search

PerkinElmer Inc

Fermé

SecteurSoins de santé

0

Résumé

Variation du prix de l'action

24h

Actuel

Min

Max

Chiffres clés

By Trading Economics

Revenu

-8.6M

47M

Ventes

-21M

699M

P/E

Moyenne du Secteur

46.938

106.172

BPA

1.18

Rendement du dividende

0.3

Marge bénéficiaire

6.675

Employés

11,000

EBITDA

-14M

181M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+20.43% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

0.30%

2.31%

Date du Prochain Détachement de Dividende

16 janv. 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-708M

11B

Ouverture précédente

0

Clôture précédente

0

Sentiment de l'Actualité

By Acuity

23%

77%

37 / 374 Classement par Healthcare

PerkinElmer Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

20 nov. 2025, 23:07 UTC

Market Talk

Evidence Of Broad Australian Economic Upswing Mounts -- Market Talk

20 nov. 2025, 22:22 UTC

Market Talk

Auckland Airport Has Edge Over Transurban In Infrastructure Stocks -- Market Talk

20 nov. 2025, 22:08 UTC

Market Talk

Revenues of Texas Battery Projects Drop Sharply -- Market Talk

20 nov. 2025, 21:57 UTC

Résultats

Walmart Reports Strong Sales Growth, Raises Outlook -- 5th Update

20 nov. 2025, 21:50 UTC

Market Talk
Acquisitions, Fusions, Rachats

Tech, Media & Telecom Roundup: Market Talk

20 nov. 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

20 nov. 2025, 21:50 UTC

Market Talk
Acquisitions, Fusions, Rachats

Health Care Roundup: Market Talk

20 nov. 2025, 21:50 UTC

Market Talk
Résultats

Financial Services Roundup: Market Talk

20 nov. 2025, 21:31 UTC

Résultats

Nvidia's Strong Results Show AI Fears Are Premature -- Update

20 nov. 2025, 21:23 UTC

Résultats
Acquisitions, Fusions, Rachats

These Stocks Moved the Most Today: Nvidia, Exact Sciences, Walmart, AMD, Alphabet, Palo Alto Networks, and More -- Barrons.com

20 nov. 2025, 21:07 UTC

Résultats

Intuit Earnings Beat Estimates as Company Leans Into AI Strategy -- Barrons.com

20 nov. 2025, 21:06 UTC

Résultats

Webull 3Q Rev $156.9M >BULL

20 nov. 2025, 21:06 UTC

Résultats

Webull 3Q EPS 7c >BULL

20 nov. 2025, 21:05 UTC

Résultats

Intuit 1Q Sales Jump, CFO Cites AI Demand From Mid-Sized Businesses -- Interview

20 nov. 2025, 21:04 UTC

Résultats

Mid-Sized Businesses Want to Automate Tasks With AI, Intuit CFO Says >INTU

20 nov. 2025, 21:04 UTC

Résultats

Intuit's AI Offerings Attracted More Mid-Sized Businesses in 1Q, CFO Says >INTU

20 nov. 2025, 21:04 UTC

Résultats

Intuit Earnings Beat Estimates as Company Leans Into AI Strategy -- Barrons.com

20 nov. 2025, 21:00 UTC

Résultats

Intuit Sees 2Q Rev $4.52B-$4.55B >INTU

20 nov. 2025, 21:00 UTC

Résultats

Intuit Sees FY26 GAAP Operating Income $5.78B to $5.86B

20 nov. 2025, 21:00 UTC

Résultats

Intuit Sees 2Q Adj EPS $3.63-Adj EPS $3.68 >INTU

20 nov. 2025, 21:00 UTC

Résultats

Intuit Expects FY26 Global Business Solutions Rev Growth of 15.5% to 16.5%, Excluding Mailchimp

20 nov. 2025, 21:00 UTC

Résultats

Intuit Expects FY26 Consumer Rev Growth of 8% to 9%

20 nov. 2025, 21:00 UTC

Résultats

Intuit Expects FY26 Global Business Solutions Rev Growth of 14% to 15%

20 nov. 2025, 21:00 UTC

Résultats

Intuit Backs FY26 Rev $21B-$21.19B >INTU

20 nov. 2025, 21:00 UTC

Résultats

Intuit Backs FY26 Adj EPS $22.98-Adj EPS $23.18 >INTU

20 nov. 2025, 21:00 UTC

Résultats

Intuit 1Q Consumer Rev $894M

20 nov. 2025, 21:00 UTC

Résultats

Intuit Sees 2Q EPS $1.76-EPS $1.81 >INTU

20 nov. 2025, 21:00 UTC

Résultats

Intuit Backs FY26 Guidance

20 nov. 2025, 21:00 UTC

Résultats

Intuit Backs FY26 EPS $15.49-EPS $15.69 >INTU

20 nov. 2025, 21:00 UTC

Résultats

Intuit 1Q Global Business Solutions Rev $3B

Comparaison

Variation de prix

PerkinElmer Inc prévision

Objectif de Prix

By TipRanks

20.43% hausse

Prévisions sur 12 Mois

Moyen 111.1 USD  20.43%

Haut 125 USD

Bas 100 USD

Basé sur 11 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

11 ratings

8

Achat

3

Maintien

0

Vente

Sentiment

By Acuity

37 / 374Classement par Soins de santé

Sentiment de l'Actualité

Très Fortes Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Supérieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos PerkinElmer Inc

Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
help-icon Live chat